A Review on Leukemia and iPSC Technology: Application in Novel Treatment and Future

Author(s): Amirhosein Maali, Amir Atashi, Sasan Ghaffari, Reza Kouchaki, Fereshteh Abdolmaleki, Mehdi Azad*.

Journal Name: Current Stem Cell Research & Therapy

Volume 13 , Issue 8 , 2018

Become EABM
Become Reviewer

Abstract:

Leukemia is an uncontrollable growth of hematopoietic cells due to a mutation in DNA followed by cellular dysregulation and one or more chromosomal disorder that generally leads to a clonal abnormality. Theoretical and technical inability in early screening and distinguishing cancer, tumor tolerance to common treatment methods, repeated relapses of cancer after remission phase, heterogeneous chromosomal abnormality, and the side effects of current chemotherapies are some of challenges that we face with leukemia and other malignancies. Induced pluripotent stem cells (iPSC) opened a promising window to a wide range of diseases, including leukemia. Overcoming the barriers in leukemia is possible with iPSC technology. Induced hematopoietic stem cell transplantation (and gene therapy), induced cytotoxic T-lymphocytes and reprogrammed NK cells that strengthen the immune system, miRNAs, modeling approaches, and supportive cares are some aspects of the novel treatment based on iPSC technology.

Keywords: Leukemia, iPSC, treatment, reprogrammed NK cells, miRNAs, gene therapy, iHSC, malignancy modeling.

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 13
ISSUE: 8
Year: 2018
Page: [665 - 675]
Pages: 11
DOI: 10.2174/1574888X13666180731155038
Price: $58

Article Metrics

PDF: 23
HTML: 1